

Activity Outline
Topics in Public Health: Statin-associated autoimmune myopathy in eight American Indian patients: Lessons and Opportunities
March 19, 2021
Webinar

Activity Coordinator:

Amy Ramanadham (Amy.Ramanadham@fda.hhs.gov), Jessica Voqui (jessica.voqui@fda.hhs.gov),

Series Description

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

Lecture Description

Statins are one of the most commonly prescribed and studied medications in the United States with significant side effects being infrequent. These medications have not been studied to the same degree in American Indian and Alaskan Native AI/AN populations. On the reservation that we serve, we have seen elevated rates of SAAM, which is typically only seen in 2-3 of every 100,000 patients treated with statins. This is a potentially life-threatening condition that necessitates additional study to determine the true impact on AI/AN populations.

References

- Close RM, Close LM, Galdun P, Gerstberger S, Rydberg M, Christopher-Stine L. Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies. Rheumatology (Oxford). 2020 Aug 13;keaa337. doi: 10.1093/rheumatology/keaa337. Epub ahead of print. PMID: 32789452.
- Tiniakou E. Statin-Associated Autoimmune Myopathy: Current Perspectives. Ther Clin Risk Manag. 2020;16:483-492. Published 2020 May 27. doi:10.2147/TCRM.S197941

Series Objectives

- Increase awareness of current topics in public health
- Help improve patient/public health outcomes
- Help participants modify their practice within their job or deployments

Learning Objectives After completion of this activity, the participant will be able to:

- Recognize the impact of statin associated autoimmune myopathy in a Native American population
- Review epidemiology, clinical presentation, and diagnostic work up of SAAM
- Discuss the public health impact of this condition

Target Audience

This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, and other public health medical professionals interested in learning more about the initiatives other advances in public health..

Agenda

Lecture 1 March 19, 2021

Time	Topic	Speaker
2:00 - 3:00 PM	Statin-associated autoimmune myopathy in eight American Indian patients: Lessons and Opportunities	Patrick Galdun, PharmD Ryan Close, MD, MPH Laura Close, DNP, FNP-BC

Continuing Education Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 0 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-21-044-L04-P, and ACPE Universal Activity Number JA0002895-0000-21-044-L04-T for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

CPH

Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

- ▣ Close, Laura, DNP, FNP-BC, Family Nurse Practitioner, Indian Health Service *nothing to disclose*
- ▣ Close, Ryan, MD, MPH, Director Preventative Medicine, Indian Health Service *nothing to disclose*
- ▣ Galdun, Patrick, PharmD, Clinical Pharmacist, Indian Health Service *nothing to disclose*

Planning Committee

- BIRCH-SMITH, POSTELLE, PharmD *nothing to disclose*
- Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS *nothing to disclose*
- Chin, Edward, MD, MPH, Medical Officer, ONDP II *nothing to disclose*
- Januszewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/ODLDC *nothing to disclose*
- La, Thang, PharmD, MPH, Central Triage Unit Manager, FDA/CDER/OSE/RSS *nothing to disclose*
- Lucero, Karly, RN, DNP, MSN/eD, CCHP, Regional Field Medical Coordinator, DHS *nothing to disclose*
- McClain, Rena, PharmD, CMS *nothing to disclose*
- Nabavian, Sadaf, Senior Regulatory Project Manager, FDA *nothing to disclose*

CE Consultation and Accreditation Team

- Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

Registration Fee and Refunds

Registration is complimentary, therefore refunds are not applicable.